Zoetis Inc (ZTS)
Pretax margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 2,940,000 | 2,881,000 | 2,832,000 | 2,629,000 | 2,659,000 | 2,573,000 | 2,564,000 | 2,531,000 | 2,491,000 | 2,405,000 | 2,343,000 | 2,189,000 | 1,998,000 | 2,014,000 | 1,945,000 | 1,917,000 | 1,801,000 | 1,782,000 | 1,672,000 | 1,656,000 |
Revenue (ttm) | US$ in thousands | 8,544,000 | 8,371,000 | 8,222,000 | 8,094,000 | 8,080,000 | 8,007,000 | 7,995,000 | 7,891,000 | 7,776,000 | 7,616,000 | 7,412,000 | 7,012,000 | 6,675,000 | 6,542,000 | 6,340,000 | 6,339,000 | 6,260,000 | 6,150,000 | 6,046,000 | 5,914,000 |
Pretax margin | 34.41% | 34.42% | 34.44% | 32.48% | 32.91% | 32.13% | 32.07% | 32.07% | 32.03% | 31.58% | 31.61% | 31.22% | 29.93% | 30.79% | 30.68% | 30.24% | 28.77% | 28.98% | 27.65% | 28.00% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $2,940,000K ÷ $8,544,000K
= 34.41%
The pretax margin of Zoetis Inc has shown a generally positive trend over the past eight quarters, ranging from 32.04% to 34.40%. The company's ability to generate earnings before taxes as a percentage of total revenue has improved consistently, with a slight dip in Q1 2023 compared to the preceding quarter. Overall, Zoetis has demonstrated a stable level of efficiency in managing operating expenses and generating profits before taxes during the period under review.
Peer comparison
Dec 31, 2023
Company name
Symbol
Pretax margin
Zoetis Inc
ZTS
34.41%
Abbott Laboratories
ABT
16.90%
AbbVie Inc
ABBV
11.49%
Alkermes Plc
ALKS
15.07%
Amphastar P
AMPH
26.28%
ANI Pharmaceuticals Inc
ANIP
4.37%
Arcus Biosciences Inc
RCUS
-257.26%
Biomarin Pharmaceutical Inc
BMRN
9.72%
Bristol-Myers Squibb Company
BMY
18.72%
Catalent Inc
CTLT
-23.44%
Catalyst Pharmaceuticals Inc
CPRX
23.73%